The CATALYST Initiative:
Expanding Knowledge to Improve Clinical Decision-Making and Health Outcomes for Patients with Hematologic Malignancies:

A Focus on CLL


Ryan Jacobs, MD 
Principal Investigator of CLL Clinical Trials
Assistant Professor, Atrium Health
Department of Hematology, Lymphoma Section
Levine Cancer Institute
Charlotte, NC

This case-based live virtual activity is designed to help community oncologists and the multidisciplinary care team choose the optimal treatment for chronic lymphocytic leukemia (CLL) based on patient and disease characteristics, including performance status, organ function, comorbidities, drug interactions, and genetic and molecular biomarkers; monitor for and manage adverse events; and implement SDM into clinical practice to improve patient care and QoL.

This multi-modular educational initiative is intended for US-based hematologists, medical oncologists, and other healthcare providers involved in the management of patients with chronic lymphocytic leukemia.

After completing the CME activity, learners should be better able to:
  • Determine how genetic and molecular markers aid in determining treatment strategies for patients with CLL
  • Differentiate therapy for the treatment of newly diagnosed or relapsed/refractory (R/R) CLL based on disease‐ and patient‐specific factors and communicate treatment plans using shared decision-making strategies
  • Distinguish adverse events associated with CLL treatment to appropriately prevent and/or manage potential effects
Powered by QuestionPro